RecruitingPhase 4NCT06498037

Optimizing Subcutaneous FEntanyl titRation: RApid Achievement of Adequate Exposure When Treating Cancer-Related paIn.


Sponsor

Erasmus Medical Center

Enrollment

45 participants

Start Date

Feb 23, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The primary objective is to evaluate the effect of loading boluses when dose incresaing treatment with SC fentanyl in patients with cancer. The primary endpoint of this study is to prove the non-inferiority of fentanyl plasma concentrations 12 hours after dose augmentation compared to 48 hours after dose augmentation within each patient. Patients will be treated with additional loading boluses and plasma-PK samples will be obtained.


Eligibility

Min Age: 18 YearsMax Age: 120 Years

Inclusion Criteria3

  • Age ≥18 years;
  • Able to understand the written information and able to give informed consent.
  • Current or planned treatment with SC fentanyl for cancer-related pain

Exclusion Criteria5

  • Pregnancy or/ and breastfeeding
  • Other ways of using fentanyl (sublingual, nasal spray and oromucosal)
  • Liver function CPS B or C
  • The use of strong CYP3A4 inhibitors of inducers \[9\]
  • Presence of somnolence, respiratory depression or CTCAE grade 2 adverse events.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFentanyl

Administration of subcutaneously administered fentanyl loading boluses


Locations(1)

Erasmus Medical Center

Rotterdam, South Holland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06498037


Related Trials